Higher Medicine develops de-risked and safe small molecules first for a rare pediatric CNS disorder, Kabuki Syndrome, and follows up on more common disorders, including autism, CTE/TBI, and Alzheimer's disease. The ultimate goal is to position the therapies as a more general, health-span solution. We work closely with Johns Hopkins experts in the field, and hold options for essential portfolio patents.